tirzepatide china approval With approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs Chinese companies turn to generics

(Caveat: A new analysis from Cleveland Clinic, involving nearly 8,000 patients, suggests that stopping drugs like semaglutide and tirzepatide (GLP1 drugs) does not typically result in major weight regain in real-world settings

Order Curb here:

For employers, these findings suggest that evaluating GLP-1s solely through pharmacy spend may overlook broader impacts on overall healthcare costs and workforce health

Venous blood samples were obtained before and after 8 weeks

Included for research reconstitution before transfer into the Aerosol spray bottle

Could GLP-1s follow similar approval trajectory and commercial growth